On October 27, 2015, the Patent Trial and Appeal Board (PTAB) denied the Coalition for Affordable Drugs' inter partes review (IPR) petition challenging Finnegan client Biogen's patent covering treatments for multiple sclerosis. This is the second IPR petition from the Coalition that the PTAB denied in regard to Biogen's patent. The Board ruled that the Coalition had not shown a reasonable likelihood that it would succeed in a trial at showing the unpatentability of the claims at issue.
Press Release
September 11, 2024
Announcement
September 3, 2024
Announcement
Finnegan and Partner Daniel Chung Recognized by The National Law Journal
September 3, 2024
Press Release
Finnegan Named a “True Trailblazer” for Its Continued Commitment to Mansfield Certification Process
August 16, 2024
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.